2,2,2-Trifluoroethyl Isocyanate - CAS 371-92-6
Catalog: |
BB057243 |
Product Name: |
2,2,2-Trifluoroethyl Isocyanate |
CAS: |
371-92-6 |
Synonyms: |
Isocyanic Acid 2,2,2-Trifluoroethyl Ester; 1,1,1-Trifluoro-2-isocyanato-ethane |
IUPAC Name: | 1,1,1-trifluoro-2-isocyanatoethane |
Description: | 2,2,2-Trifluoroethyl Isocyanate is an intermediate used to prepare PDE5 inhibitors for erectile dysfunction. It is also used to synthesize indazolyl glucocorticoid receptor partial agonists. |
Molecular Weight: | 125.05 |
Molecular Formula: | C3H2F3NO |
Canonical SMILES: | C(C(F)(F)F)N=C=O |
InChI: | InChI=1S/C3H2F3NO/c4-3(5,6)1-7-2-8/h1H2 |
InChI Key: | YQOWUQLKOIACGC-UHFFFAOYSA-N |
Solubility: | Chloroform, Methanol |
Appearance: | Clear Colourless Oil |
Storage: | Refrigerator, under inert atmosphere |
References: | Boyle, C., et al. Bioorg. Med. Chem. Lett., 15, 2365 (2005); Gilmore, J., et al. Bioorg. Med. Chem. Lett., 23, 5448 (2013). |
GHS Hazard Statement: | H302 (95%): Harmful if swallowed [Warning Acute toxicity, oral] |
Precautionary Statement: | P261, P264, P264+P265, P270, P271, P280, P284, P301+P317, P302+P352, P304+P340, P305+P351+P338, P317, P319, P321, P330, P332+P317, P337+P317, P342+P316, P362+P364, P403+P233, P405, and P501 |
Signal Word: | Danger |
Publication Number | Title | Priority Date |
WO-2021249913-A9 | 2'-(quinolin-3-yl)-5',6'-dihydrospiro[azetidine-3,4'-pyrrolo[1,2-b]pyrazole]-1-carboxylate derivatives and related compounds as map4k1 (hpk1) inhibitors for the treatment of cancer | 20200609 |
WO-2021222522-A1 | Cd73 inhibiting 2,4-dioxopyrimidine compounds | 20200501 |
WO-2021004547-A1 | Heterocyclic compounds as inhibitors of hpk1 | 20190711 |
WO-2020115501-A1 | Pharmaceutical compounds and their use as inhibitors of ubiquitin specific protease 19 (usp19) | 20181206 |
AU-2019393162-A1 | Pharmaceutical compounds and their use as inhibitors of Ubiquitin Specific Protease 19 (USP19) | 20181206 |
CA-3121376-A1 | Pharmaceutical compounds and their use as inhibitors of ubiquitin specific protease 19 (usp19) | 20181206 |
CN-113365696-A | Pharmaceutical compounds and their use as inhibitors of ubiquitin-specific protease 19(USP19) | 20181206 |
EP-3890829-A1 | Pharmaceutical compounds and their use as inhibitors of ubiquitin specific protease 19 (usp19) | 20181206 |
IL-283706-D0 | Pharmaceuticals and their use as inhibitors of specific 19 protease of ubiquitin | 20181206 |
KR-20210102285-A | Use as pharmaceutical compounds and inhibitors of ubiquitin-specific protease 19 (USP19) | 20181206 |
Complexity: | 112 |
Compound Is Canonicalized: | Yes |
Covalently-Bonded Unit Count: | 1 |
Defined Atom Stereocenter Count: | 0 |
Defined Bond Stereocenter Count: | 0 |
Exact Mass: | 125.00884817 |
Formal Charge: | 0 |
Heavy Atom Count: | 8 |
Hydrogen Bond Acceptor Count: | 5 |
Hydrogen Bond Donor Count: | 0 |
Isotope Atom Count: | 0 |
Monoisotopic Mass: | 125.00884817 |
Rotatable Bond Count: | 1 |
Topological Polar Surface Area: | 29.4Ų |
Undefined Atom Stereocenter Count: | 0 |
Undefined Bond Stereocenter Count: | 0 |
XLogP3: | 2.1 |
Online Inquiry
Customer Support
Customer Centered
Related Functional Groups
Other Building Blocks
Customers Also Viewed
INDUSTRY LEADERS TRUST OUR PRODUCTS